MARKET

IRON

IRON

Disc Medicine Inc
NASDAQ
74.78
+4.62
+6.58%
After Hours: 78.44 +3.66 +4.89% 19:48 06/26 EDT
OPEN
70.21
PREV CLOSE
70.16
HIGH
75.00
LOW
69.44
VOLUME
1.90M
TURNOVER
--
52 WEEK HIGH
99.50
52 WEEK LOW
40.00
MARKET CAP
2.86B
P/E (TTM)
-11.3180
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 1d ago
Disc Medicine COO Jonathan Yen-Wen Yu disposes of 9,700 common shares worth $704,795
PUBT · 3d ago
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 3d ago
Disc Medicine Stockholders Approve Governance and Executive Pay
TipRanks · 3d ago
Disc Medicine shareholders approve advisory executive pay vote
PUBT · 3d ago
Disc Medicine CEO John Quisel disposes of common shares worth $2.38 million
PUBT · 4d ago
Weekly Report: what happened at IRON last week (0615-0619)?
Weekly Report · 5d ago
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 06/19 18:07
More
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Webull offers Disc Medicine Inc stock information, including NASDAQ: IRON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRON stock methods without spending real money on the virtual paper trading platform.